Skip to content

RYANSpecialty insurance brokerage

Ryan Specialty

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$47.07
Intrinsic value
Intrinsic value from an AI estimate
Discount category
Close to intrinsic value (AI estimate)
Analysts
Leaning bullish
Next earnings
Jan 29 · · estimated
Pick status
Research only

In short

Thesis
The market weighs the strong record of Ryan Specialty against slower growth in a more difficult insurance market, and steady organic growth with a stable margin in 2027 can lift its value.
Gap
Slow. Organic growth and margins depend on the insurance market, and the savings of the Empower program come only by 2029.

Company guidance: 2026 organic revenue growth in the mid-single digits; adjusted EBITDAC margin down modestly from 2025 (, Q3 2026 results release)

Price history

About

Ryan Specialty Holdings, Inc. (Ryan Specialty) is a specialty insurance firm. It works as a wholesale broker for retail insurance brokers, places risks with insurers through binding authority, and acts as a managing underwriter with authority that insurers delegate to it. It earns commissions and fees, and it does not take insurance risk itself. Total revenue was $2,501.8 million in the first nine months of 2026.

Patrick G. Ryan founded the firm in 2010 and is its Executive Chairman. The public owns Class A shares, and other holders own LLC Common Units that they can exchange for Class A shares. Ryan Specialty reports in US dollars, and its Class A shares trade on the NYSE.

Thesis

The market weighs the strong record of Ryan Specialty against slower growth in a more difficult insurance market. Organic revenue growth fell to 4.0% in Q3 2026, from 15.0% in Q3 2025, as most casualty lines grew but the property portfolio declined. Debt also rose to $3.7 billion as Ryan Specialty bought back shares and made acquisitions. The AI estimate uses a multiple of 2027 adjusted earnings per share.

For the price to rise, three things must be true. Organic growth must stay in the mid-single digits or rise, as more risks move to the specialty market. The Empower program must give the savings that Ryan Specialty expects, about $80 million a year by 2029, so that the adjusted EBITDAC margin stops falling. Share buybacks and acquisitions must add to adjusted earnings per share while debt stays at a level the firm can carry.

The Q4 2026 results and the 2027 outlook, expected about January 29, 2027, are the next test, and the results of 2027 show the trend. If the property business declines more or casualty growth slows, the price can stay low.

Valuation

AI estimate, checked by Kevin. How it is made

Show the method

The intrinsic value for Ryan Specialty is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Ryan Specialty. The method is a multiple of adjusted diluted earnings per share (EPS) for 2027, less the liability under the tax receivable agreement per share.

Adjusted EPS leaves out the amortization of acquired intangible assets, changes in contingent consideration, restructuring costs and some equity-based pay, and it counts all LLC Common Units as exchanged for Class A shares. The Q3 2026 results (Form 8-K of October 29, 2026) give adjusted diluted EPS of $0.51 for Q3 2026 and $1.75 for the first nine months, on an adjusted diluted share count of 266.3 million for Q3. The Q4 2025 results of February 12, 2026 give adjusted diluted EPS of $0.45 for Q4 2025 and $1.96 for 2025. The estimate assumes 2026 adjusted EPS of about $2.22: $1.75 for the first nine months plus about $0.47 for Q4.

Because EPS is after interest, the estimate makes no separate debt adjustment. The Form 10-Q gives debt principal of $3,693.1 million and cash and cash equivalents of $168.8 million at September 30, 2026. It also gives tax receivable agreement liabilities of $454.4 million, which the estimate subtracts at $1.71 per share. The cover of the Form 10-Q gives 119,694,115 Class A shares and 131,887,106 Class B shares at October 26, 2026.

Each Class B share goes with an LLC Common Unit that its holder can exchange for a Class A share. The 2027 adjusted EPS and the multiples are assumptions. The low case assumes adjusted EPS of $2.20, because insurance prices fall and organic growth stays low, at 16 times. It gives $33.49 per share.

The base case assumes $2.40, about 8% more than in 2026, with savings from the Empower program and share buybacks, at 20 times. It gives $46.29 per share. The high case assumes $2.60 at 24 times. It gives $60.69 per share.

The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $46.69 per share. Ryan Specialty is a large wholesale broker and managing underwriter. Retail brokers and insurers depend on its specialists, its access to many insurance markets and the authority that insurers delegate to it, and these relations take years to build.

These give an advantage that can last 10 years or more. But other wholesale brokers compete for the same business, and brokers can leave and take clients with them. The estimate uses no results after September 30, 2026.

Checkpoints

  1. Jan 29, 2027 · est.Pending
    Q4 2026 results: organic growthOrganic revenue growth for Q4 2026 is 4% or more and adjusted diluted earnings per share are above the $0.45 of Q4 2025, and this passes; lower growth or lower earnings per share fails.
  2. 2027 · est.Pending
    2027 margin and Empower savingsThe adjusted EBITDAC margin for 2027 is equal to or above the margin for 2026, and this passes; a lower margin fails.

Every passed and failed checkpoint across all picks

Recent events

  • October 29, 2026Ryan Specialty reported Q3 2026 results. Total revenue grew 4.7% to $790.0 million, with organic growth of 4.0%. Adjusted EBITDAC grew 3.8% to $244.4 million, and adjusted diluted earnings per share grew 8.5% to $0.51. It repurchased $150.0 million of Class A shares and declared a quarterly dividend of $0.13 per share.
  • July 30, 2026Ryan Specialty reported Q2 2026 results. Total revenue grew 7.2% to $916.6 million, with organic growth of 6.7%, and adjusted diluted earnings per share grew 12.1% to $0.74. It repurchased $260.0 million of Class A shares in the quarter.
  • May 26, 2026The board increased the share repurchase authorization by $300 million, after the company used the prior $300 million authorization.
Show 2 older events
  • April 30, 2026Ryan Specialty reported Q1 2026 results, with revenue growth of 15.2% to $795.2 million and organic growth of 11.8%. It also agreed that a trust of Patrick G. Ryan will sell it shares when employees exercise new stock options, so that the options do not add shares.
  • February 12, 2026Ryan Specialty reported Q4 2025 results, with organic growth of 6.6% and adjusted diluted earnings per share of $0.45. It announced a $300 million share repurchase authorization and the Empower restructuring program, which should cost about $160 million and save about $80 million a year in 2029.

Latest news and filings

Last earnings
October 29, 2026 (8-K on sec.gov)
Next earnings
Expected about January 29, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 1849253)

Risks

  • Commissions depend on insurance prices and on the flow of risks to the specialty market. Organic growth fell to 4.0% in Q3 2026 from 15.0% a year earlier, and the property portfolio declined.
  • Debt principal was $3,693.1 million at September 30, 2026, and $422.8 million was drawn on the revolving credit facility. The term loan has a floating rate.
  • The tax receivable agreement liabilities were $454.4 million at September 30, 2026, and exchanges of LLC Common Units can increase them.
  • Brokers and underwriters are the main asset. If key people leave for competitors, they can take clients and insurer relations with them.
  • Holders of LLC Common Units own about half of the firm and can exchange them for Class A shares and sell them.

Key statistics

Market cap
$12B
Shares of Oct 26, 2026
Yield at current rate
1.1%
Current annual rate, at the price of Nov 20, 2026
Dividend yield
1.1%
Last 12 months, at the price of Nov 20, 2026
52-week range
$29.28 – $58.91
To Nov 13, 2026
Beta
0.54
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
2.0M
3 months, to Nov 13, 2026

Balance sheet

Cash
$169M
Debt
$3.7B
Net debt
$3.5B
Net debt / EBITDA
3.4×
EBITDA $1.0B, last 12 months
Credit line
$977M
undrawn

Cash against debt

Cash$169M
Debt$3.7B

debt covered by cashnet debt $3.5B

Leverage: net debt / EBITDA

low, under 2×medium, 2× to 4×high, over 4×

When the debt is due

12 months$42M
Later$3.7B

The last debt is due in 2032.

At September 30, 2026, debt principal was $3,693.1 million: a term loan of $1,670.3 million, $422.8 million drawn on the revolving credit facility, $400.0 million of senior secured notes due 2030 and $1,200.0 million of senior secured notes due 2032. Cash and cash equivalents were $168.8 million, and $977.2 million of the revolving credit facility was available.

Dividends

Yield at the current rate
1.1% (current annual rate, at today’s price)
Dividend yield
1.1% (last 12 months, at today’s price of $47.07)
Paid per share
$0.52 in the last 12 months (4 payments)
Current annual rate
$0.52 ($0.13 × 4 a year)
Latest ex-dividend date
November 10, 2026, $0.13 per share

Dividends per share by year

Ryan Specialty dividends per share by year
2025
$0.48

Some payments of 2024 are missing in the data, so no bar is shown for that year.

One-off payments far above the usual dividend are left out of these numbers.

Source: company filings and market data, read on November 13, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.

Questions about Ryan Specialty

What does Ryan Specialty do?

Ryan Specialty Holdings, Inc. (Ryan Specialty) is a specialty insurance firm. It works as a wholesale broker for retail insurance brokers, places risks with insurers through binding authority, and acts as a managing underwriter with authority that insurers delegate to it. Its market cap is $12B at the current price of $47.07.

When does Ryan Specialty report earnings next?

This is an estimate: Ryan Specialty may report on January 29, 2027. It last reported results on October 29, 2026.

Is Ryan Specialty stock below its intrinsic value?

Ryan Specialty stock is close to intrinsic value. The source of the intrinsic value is: AI estimate. This is general information, not advice.

What changed recently at Ryan Specialty?

The latest update is from October 29, 2026. Ryan Specialty reported Q3 2026 results.

What are the main risks for Ryan Specialty?

Commissions depend on insurance prices and on the flow of risks to the specialty market. Debt principal was $3,693.1 million at September 30, 2026, and $422.8 million was drawn on the revolving credit facility. The tax receivable agreement liabilities were $454.4 million at September 30, 2026, and exchanges of LLC Common Units can increase them.

How much debt and cash does Ryan Specialty have?

At September 30, 2026, Ryan Specialty had $3.7B of debt and $169M of cash.

Does Ryan Specialty pay a dividend?

Yes. The current annual dividend of Ryan Specialty is $0.52 per share. That is a dividend yield of 1.1% at the current price of $47.07. The latest ex-dividend date was November 10, 2026.

Similar companies

  • AONAonShares: High debt
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • IFFInternational Flavors & FragrancesShares: High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • APGAPi GroupShares: High debt
    Intrinsic value
    Close to intrinsic value (AI estimate)
    Gap
    Slow
  • SNPSSynopsysShares: High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • AZOAutoZoneShares: High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star RYAN or pass, then go on to the next one.